Strategic Partnerships Carenostics has established collaborations with large pharma players, government agencies, and healthcare organizations (including AstraZeneca, VA, Hackensack Meridian Health) which indicates a sales path targeting integrated care strategies, payer collaborations, and enterprise deployments of CKDx within large networks.

Clinical Impact The CKDx platform targets undiagnosed chronic kidney disease and aims to reduce disparities while projecting decline to support guideline-based treatment, presenting a compelling value proposition for health systems seeking early intervention, risk stratification, and equity-driven outcomes.

AI in Care Carenostics leverages AI and EHR-integrated decision support, a strong fit for hospital systems prioritizing AI-enabled CDI (clinical decision support) and workflow-embedded tools, enabling upsell to surgeons, nephrology, primary care, and care management teams.

Growth Signals Recent recognition as rising star in AI and multiple finalist/award notices, plus seed funding and notable partnerships, create momentum for enterprise pilots and expansion into payer networks and academic collaborations, reducing perceived risk for new customers.

Market Positioning Operating in hospitals and healthcare with small but scalable team (11-50 employees) and a clear focus on equity and chronic disease care positions Carenostics to pursue mid-market health systems and integrated delivery networks seeking targeted CKD interventions and cost containment.